Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Gina Somaini (Zurich, Switzerland), Gina Somaini, Adriana Stamm, Sévérine Müller-Mottet, Elisabeth Hasler, Keusch Stephan, Hildenbrand Florian, Rudolf Speich, Michael Furian, Konrad Bloch, Silvia Ulrich. Disease-targeted treatment improves cognitive function in patients with pulmonary hypertension. Eur Respir J 2015; 46: Suppl. 59, 2116

Member's Comments

No comment yet.

Related content which might interest you: The influence of psycho-social factors in the evolution of pulmonary hypertension patients Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Anxiety and depression are highly prevalent in pulmonary hypertension and might improve with target therapy Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Systemic vascular function in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Acute and chronic effects of PDE5-Is on SpO2 in patients with COPD associated pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Exercise tests and anxiety independently reflect physical quality of life in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Riociguat improves excessive exercise ventilation in patients with inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Predictors of success and failure in pulmonary rehabilitation Source: Eur Respir J 2006; 27: 788-794 Year: 2006 Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Severe pulmonary hypertension in patients with emphysema but preserved FEV1: Prognosis and response to treatment Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016